SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lupin gains on launching generic Tobramycin Inhalation Solution USP in US

14 Jun 2018 Evaluate

Lupin is currently trading at Rs. 878.55, up by 8.95 points or 1.03% from its previous closing of Rs. 869.60 on the BSE.

The scrip opened at Rs. 876.25 and has touched a high and low of Rs. 885.05 and Rs. 863.50 respectively. So far 160394 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1194.00 on 15-Jun-2017 and a 52 week low of Rs. 723.55 on 15-May-2018.

Last one week high and low of the scrip stood at Rs. 885.05 and Rs. 764.00 respectively. The current market cap of the company is Rs. 39741.61 crore.

The promoters holding in the company stood at 47.01%, while Institutions and Non-Institutions held 37.60% and 15.40% respectively.

Pharmaceuticals Corporation’s Tobi 300 mg/5 ml

Lupin has launched its Tobramycin Inhalation Solution USP, having received an approval from the United States Food and Drug Administration (USFDA) earlier.

Lupin’s Tobramycin Inhalation Solution USP, 300 mg/5 ml is the generic equivalent of Novartis Pharmaceuticals Corporation’s Tobi 300 mg/5 ml. It is indicated for the management of cystic fibrosis patients with P. aeruginosa.

Tobramycin Inhalation Solution USP, 300 mg/5 ml had annual sales of around $99 million in the US (IQVIA MAT April 2018).

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

Lupin Share Price

2513.00 23.15 (0.93%)
08-Jul-2026 10:25 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1910.05
Dr. Reddys Labs. 1369.95
Cipla 1454.05
Zydus Lifesciences 1170.15
Lupin 2513.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: